NCT03264547View on ClinicalTrials.gov

A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

PHASE3CompletedINTERVENTIONAL

Enrollment

446

Participants

Timeline

Start Date

August 28, 2017

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Breast Cancer

Interventions

DRUG

Pertuzumab

Every 3 weeks

DRUG

Trastuzumab

Every 3 weeks

DRUG

Docetaxel

Every 3 weeks

DRUG

Paclitaxel

Every week

DRUG

Eribulin

Administered for 2 weeks and is then stopped to be administered for 1 week

Trial Locations (2)

241-8515

Kanagawa Cancer Center, Yokohama

540-0006

National Hospital Organization Osaka National Hospital, Osaka

All Listed Sponsors

collaborator

Eisai Co., Ltd.

INDUSTRY

lead

Japan Breast Cancer Research Group

OTHER

NCT03264547 - A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab | Biotech Hunter | Biotech Hunter